← Oncology Approval Tracker

FDA DECISION ·

Exkivity

mobocertinib · Takeda

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Jul 15, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 20 insertion by an FDA-approved test, progressing during or after platinum chemotherapy. FDA withdrew this indication on July 15, 2024.

LAMPGEN ANALYSIS

Why it matters

The original accelerated approval was followed by withdrawal, which affects historical comparisons of post-platinum options.

What research teams should watch

Record exact EGFR genotype, platinum history and both FDA action dates.

PRIMARY RECORDS

Sources